Drug Profile
Research programme: scar, wound and fibrosis therapeutics - Symic Bio
Alternative Names: SBR-294Latest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator SYMIC Biomedical
- Developer Symic Bio
- Class Antifibrotics; Eye disorder therapies; Skin disorder therapies
- Mechanism of Action Inflammation mediator modulators; Platelet activating factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Corneal injuries; Fibrosis; Hepatic fibrosis; Scars; Wounds
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Hepatic-fibrosis in USA
- 28 Feb 2019 No recent reports of development identified for preclinical development in Fibrosis in USA (Parenteral)
- 28 Feb 2019 No recent reports of development identified for preclinical development in Scars in USA (Intralesional)